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Abstract Arterial hypertension is very common in children
with all stages of chronic kidney disease (CKD). While
fluid overload and activation of the renin–angiotensin
system have long been recognized as crucial pathophysiol-
ogical pathways, sympathetic hyperactivation, endothelial
dysfunction and chronic hyperparathyroidism have more
recently been identified as important factors contributing to
CKD-associated hypertension. Moreover, several drugs
commonly administered in CKD, such as erythropoietin,
glucocorticoids and cyclosporine A, independently raise
blood pressure in a dose-dependent fashion. Because of the
deleterious consequences of hypertension on the progres-
sion of renal disease and cardiovascular outcomes, an active
screening approach should be adapted in patients with all
stages of CKD. Before one starts antihypertensive treat-
ment, non-pharmacological options should be explored. In
hemodialysis patients a low salt diet, low dialysate sodium
and stricter dialysis towards dry weight can often achieve
adequate blood pressure control. Angiotensin-converting
enzyme (ACE) inhibitors and angiotensin receptor blockers
are first-line therapy for patients with proteinuria, due to
their additional anti-proteinuric properties. Diuretics are a
useful alternative for non-proteinuric patients or as an add-
on to renin–angiotensin system blockade. Multiple drug
therapy is often needed to maintain blood pressure below
the 90th percentile target, but adequate blood pressure






Hypertension is one of the most common sequelae of
chronic kidney disease (CKD) in children [1]. CKD-
associated hypertension develops by a large variety of
pathophysiological mechanisms. Blood pressure is one
of the most critical determinants of the progression rate of
renal failure in children [2, 3], and cardiovascular mortality
in childhood onset renal failure [4]. Therefore, good
antihypertensive management can substantially contribute
to better renal and patient survival of adults with childhood-
onset CKD.
As in many other complications of chronic renal failure,
patients often do not report symptoms of hypertension, so
an active screening approach is needed to prevent end-
organ damage.
This article aims to give a short overview of the different
pathophysiological pathways that lead to hypertension in
CKD in order to explain how these can be targeted by
different therapeutic approaches.
Pathophysiology of hypertension in CKD
Fundamentally, increased blood pressure is caused by an
increase in cardiac output and/or of total peripheral resistance.
Both can be altered by a plethora of different mechanisms in
uremia and renal failure. Additionally, children with certain
underlying diseases, e.g. glomerulopathies and polycystic
kidney disease, are especially susceptible to hypertension [3,
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Activation of the renin–angiotensin–aldosterone system
plays a pivotal role in renal hypertension. While plasma
renin activity is typically found to be markedly elevated
only in patients with renal artery stenosis, many patients
with CKD have ‘inappropriately normal’ renin levels (i.e.
lower levels would be expected, considering their degree of
hypertension and fluid overload [6, 7]). Hyper-reninemia
occurs probably due to renin secretion in poorly perfused
areas such as cysts and scars or after microangiopathic
damage or tubulo-interstitial inflammation [8, 9] and leads
to angiotensin II-mediated vasoconstriction as well as
aldosterone-mediated salt retention, thus increasing both
total peripheral resistance and blood volume. Additional
delayed effects of a high angiotensin II tone include
inflammation, cardiac hypertrophy and endothelial cell
damage, mesangial cell proliferation and fibrosis [10],
which contribute further to hypertension and end-organ
damage.
Sodium retention and consequent fluid overload have
long been recognized as causes of hypertension in CKD.
Hypertensive children on dialysis have lower residual urine
output than their normotensive peers have [5]. While inter-
dialytic weight gain is correlated with the inter-dialytic
increase in ambulatory blood pressure, the correlation is
rather weak (in children r=0.41 [11]). This may be due to
delayed effects [12] but also points to important volume-
independent factors regulating blood pressure (BP) in
patients on hemodialysis. This is also illustrated by the fact
that nephrectomy in children on dialysis lowers mean blood
pressure, despite causing anuria [13]. It has been proposed
that fluid overload leads to hypertension only in those
patients in whom peripheral resistance fails simultaneously
to fall, i.e. when additional factors interfere with vascular
autoregulation [14].
A growing body of evidence suggests that increased
activity of the sympathetic nervous system (SNS) is an
important volume-independent cause of hypertension.
Campese et al. demonstrated that renal denervation
improves both hypertension and increased sympathetic
activity caused by phenol injection into rat kidneys [15].
Muscle sympathetic nerve activity is also elevated in
hypertensive patients with chronic renal failure [16]. The
underlying mechanisms of this phenomenon are, as yet,
unclear and may include afferent signals from the failing
kidney as well as dopaminergic abnormalities and the
accumulation of leptin in CKD [17, 18]. Interestingly, not
only beta blockade but also angiotensin-converting enzyme
(ACE) inhibition can reduce the sympathetic hyperactiva-
tion of CKD [16, 19]. However, as sympathetic hyperac-
tivity is also a feature of renovascular hypertension [20],
essential hypertension and hypertensive patients with
polycystic kidney disease [13], it appears that sympathetic
activation also occurs independently of renal function. The
most established cause for sympathetic over-activation is
renal ischemia caused by renal artery stenosis [20, 21], but
renal cysts might also cause local renal ischemia.
While children with end-stage renal disease (ESRD)
usually have normal plasma noradrenaline and adrenalin
concentrations, hemodialysis per se leads to substantial
increase in both plasma renin activity and catecholamines,
which can contribute to hypertension [22].
Recent experimental evidence suggests that renalase—an
amine oxidase specifically expressed by the kidney—
lowers blood pressure and heart rate. Its activity is
markedly reduced in patients with ESRD [23]. However,
whether the cardiovascular effects of this enzyme are really
due to its catecholamine-metabolizing activity is still
controversial [24].
There has been debate about the role of nitric oxide (NO)
in mediating endothelial cell damage and hypertension in
CKD. Newer studies have demonstrated that, in uremic
patients, reduced NO stimulation leads to reduced agonist-
induced endothelium-dependent vasodilatation, whereas
other vasodilatory pathways are not affected. Renal failure
leads to the accumulation of endogenous NO synthase
inhibitors such as asymmetric dimethyl-L-arginine
(ADMA), which appears to be due to increased generation
and decreased metabolism rather than decreased clearance
[25]. ADMA independently predicts overall mortality and
cardiovascular events in patients with ESRD [26], as well as
progression of CKD [27]. While ADMA is related to blood
pressure in animal models of CKD, clinical studies have not
found differences in blood pressure [25].
Endothelial NO synthase is also suppressed by hyper-
parathyroidism in rats with CKD [28]. In contrast to
ADMA levels, those of serum parathyroid hormone (PTH)
correlate highly with blood pressure in patients with CKD
[29]. Whereas acute infusion of PTH has a hypotensive
effect, chronic hyperparathyroidism leads to accumulation
Fig. 1 Interplay of different factors in the generation of hypertension
in chronic kidney disease (BP blood pressure, CO cardiac output, TPR
total peripheral resistance, PTH parathyroid hormone, Na sodium)
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their sensitivity to calcium and norepinephrine [30, 31].
This effect can be blocked by calcium channel antagonists.
A number of drugs commonly administered in CKD can
cause iatrogenic hypertension. For example, erythropoietin
(EPO) causes blood pressure elevation over several weeks.
This may be via arterial wall remodeling, causing increased
vascular resistance [32]. Vaziri et al. have proposed that
EPO acts directly on voltage-independent calcium channels
in smooth muscle cells, leading to a decreased sensitivity to
the vasodilatory action of nitric oxide [33]. The resulting
possibility of calcium channel antagonists as ‘specific’
therapy for EPO-induced hypertension has been success-
fully tested in rats [34].
Glucocorticoids lead to fluid retention by their mineral-
ocorticoid effect. Cyclosporine A causes vasoconstriction
of glomerular afferent arterioles and hyperplasia of the
juxtaglomerular apparatus, with subsequent increased re-
lease of renin and angiotensin II [35]. Increased circulating
catecholamines and endothelin-1 precursors, and increased
renal sodium absorption via the Na-K-2Cl co-transporter in
the loop of Henle [36], have also been demonstrated after
cyclosporine A treatment. Tacrolimus appears to be less
pro-hypertensive than cyclosporine in children after renal
transplantation [37], but, for other reasons, it is less
commonly used prior to transplantation [38].
Treatment with growth hormone leads to water and
sodium retention by the distal nephron [39], mediated by
increased intra-renal insulin-like growth factor (IGF)-1.
However, growth hormone (GH) does not appear to
increase blood pressure in children with CKD or Turner
syndrome, despite both groups being prone to hypertension
[40, 41].
Management
Owing to the lack of acute symptoms and to the serious
long-term consequences of hypertension, an active screen-
ing approach is necessary to detect elevated blood pressures
early and to prevent end-organ damage [42]. In contrast
to other complications of CKD, which become prevalent
only in later stages of CKD, hypertension is already very
common in CKD stage 1, with over 63% of children
affected. In CKD stages 4 and 5 the incidence increases
further to 80% [1]. More than 50% of children with ESRD
have uncontrolled hypertension, despite widespread use of
antihypertensive drugs [5, 43]. The frequency of blood
pressure measurement during screening and during therapy
should be appropriate to the patient’s risk of developing
uncontrolled hypertension. A routine for this is suggested in
the flow chart in Fig. 2. In general, we would consider all
children with CKD to be at least at intermediate risk, and,
therefore, we recommend 3-monthly clinic blood pressure
(CBP) measurements; children with ESRD, multiple pro-
hypertensive medications or confirmed hypertension should
be considered as at high risk. In our experience 24 h
ambulatory blood pressure measurement (ABPM) is a very
valuable tool and should be performed annually in high-risk
populations such as renal transplant recipients or those with
rapidly progressive renal disease. ABPM is also useful to
exclude white-coat hypertension, which is a problem even
in children under long-term medical care [44]. While there
are equivocal results about the long-term consequences of
white-coat hypertension, end-organ damage could be
clearly demonstrated in children with masked hypertension,
i.e. elevated ABPM but normal CBP [45], underlining the
usefulness of this method.
Whichever method is used, techniques should be in
accordance with international consensus statements, and the
appropriate pediatric reference ranges are very important.
These are now available for clinic [46, 47], ambulatory [48]
and home blood pressure measurements [49]. The diagnosis
of hypertension should be based on at least three clinic
blood pressure measurements above the 95th percentile
[46]. As white-coat hypertension is very common, and the
effects of thorough investigation and treatment can be far-
reaching, we feel ABPM is advisable in nearly all newly
diagnosed hypertensive children. In countries where health
care providers do not cover the cost of ABPM, home blood
pressure measurements may be helpful in confirming the
diagnosis, but they do not pick up the nocturnal blood
pressure dynamics [44].
Once hypertension has been confirmed, good manage-
ment should not focus only on pharmacological therapy, but
also on detection and treatment of end-organ damage and,
where appropriate, improvement of the dialysis regime and
consideration of therapeutic life-style changes.
Echocardiography and ophthalmological examination
are the most important assessments of end-organ damage
in hypertensive children. Left ventricular hypertrophy
(LVH) is common in children with CKD, even during
antihypertensive therapy [50]. LVH in patients with normal
clinic blood pressure may indicate masked hypertension in
untreated children [45] or insufficient efficacy of antihy-
pertensive drug therapy in treated children (e.g. insufficient
dose, non-compliance, or short duration of action of
selected antihypertensive drugs). Echocardiography and
ophthalmological evaluation should be repeated at regular
intervals in children with initial signs of end-organ damage
[46]. From personal experience we would also recommend
follow-up examination in children with persistent hyperten-
sion or in those at high risk (e.g. ESRD). Additional assess-
ments of end-organ damage include measurement of carotid
intima media thickness and of pulse wave velocity, which
reflect functional alterations of arterial wall properties caused
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ism [51]. These investigations are still mainly used for
research purposes, but clinical use has been facilitated by the
recent provision of pediatric reference ranges [52].
In hypertensive patients who are undergoing renal
replacement therapy, improvement of the dialysis prescrip-
tion should be the primary therapeutic approach to
hypertension, before pharmacological treatment is started.
Extracellular volume overload can be efficiently reduced by
adequately long dialysis times. Even though the reduction
of fluid overload may take several weeks to translate into
normalized blood pressure, drug-free control of hyperten-
sion is possible in many, if not most, hemodialysis patients
[12]. A number of studies have shown improved BP control
with short daily, long intermittent or nocturnal hemodialysis
[53]. While conventional dialysis schedules can also
improve control of hypertension by targeting dry weight
more aggressively [54], this tends to be tolerated less well,
with more intra-dialytic hypotensive episodes. Lower
concentrations of dialysate sodium also produce a moderate
fall in blood pressure on a population level, with best
results in patients with previously high blood pressure [55].
In addition to intensified dialysis, dietary sodium
restriction is a useful adjunct to intensified dialysis in
avoiding sodium overload, and it reduces intra-dialytic
hypotensive episodes. Indeed, some authors find dietary
sodium restriction plus low sodium dialysate to be equally
effective as time-intensified dialysis, and they maintain that
with good dietary advice a low salt diet need not be
unpalatable [56]. However, restriction of fluid and salt
intake requires considerable patient motivation, which is
often a problem in the adolescent population.
Therapeutic life-style changes can be effective in
lowering blood pressure if obesity contributes to the
patient’s hypertension. Obesity in children with CKD is
uncommon and usually associated with steroid treatment;
however, it is seen more commonly in populations with a
higher background risk of obesity [3]. While weight loss
can be effective in reducing blood pressure in overweight
children with normal renal function [57], unfortunately,
there are no controlled studies of life-style interventions in
children with CKD. In our experience calorie-reduced diets
are rarely effective in this population, probably due to the
multifactorial etiology of hypertension in renal disease.
Fig. 2 Flow diagram for the
choice of method to measure
blood pressure during screening,
follow up and treatment (CBP
clinic blood pressure ABPM
24 h ambulatory blood pressure
monitoring, HBP home blood
pressure measurement BP blood
pressure, BMI body mass index)
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may be hard to achieve if a potassium- and phosphate-
reduced diet is also necessary. Interestingly, weight loss
improves salt-induced increases in blood pressure in obese
children [58]; therefore, combined calorie- and sodium-
reduced diets may be particularly effective in obese CKD
children who are salt retainers.
Pharmacological treatment remains the mainstay of
antihypertensive management in all stages of CKD. In
approximately 75% of children with CKD stages 2–4,
blood pressure control below the 95th percentile can be
achieved by antihypertensive monotherapy, but 50–60% of
children need more than one drug if intensified BP control
(<50th percentile) is targeted [Effect of Strict Blood
Pressure Control and ACE Inhibition on Progression of
CRF in Pediatric Patients (ESCAPE) trial, unpublished
results]. In children with ESRD adequate control is much
harder to achieve: a review of the North American Pediatric
Renal Transplant Cooperative study (NAPRTCS) database
also showed that over 50% of children on dialysis have
uncontrolled hypertension [43], and a Polish nationwide
survey found that in only 57% of children with ESRD was
hypertension adequately controlled, despite the use of
multiple drug therapy in 65% [5].
Even though multiple drug therapy is often required, it is
advisable to start with a single drug at a low dose and to
titrate upward until blood pressure is controlled [46].
Exceptions are hypertensive emergencies, such as hyper-
tensive encephalopathy, when intravenous (i.v.) treatment
should be started promptly.
ACE inhibitors and angiotensin II type 1 receptor
blockers (ARBs) are the most useful drugs, as they are
not only antihypertensive but also slow down the progres-
sion of renal failure more efficiently than do other
antihypertensive treatments [59]. Surveys among pediatric
nephrologists from both sides of the Atlantic show that
ACE inhibitors are increasingly popular and are now the
most commonly used drugs for pediatric hypertension [60,
61]. The renoprotective effect of renin–angiotensin system
(RAS) blockade is due to a combination of reduced
proteinuria, lower intra-glomerular pressure through selec-
tive dilatation of the glomerular efferent arteriole, and anti-
inflammatory and anti-fibrotic effects [10]. Additionally,
RAS inhibition reduces the sympathetic hyperactivity seen
in CKD [16].
There is convincing evidence from studies of adults that
all proteinuric patients should receive renin–angiotensin
system blockade, even if they do not have hypertension
[42]. Major side effects are a moderate increase of
potassium and creatinine; these should be monitored more
closely with declining renal function. Sexually active
adolescent girls must use contraception. ACE inhibitor-
induced cough appears to be less common in children than
in adults [62]. There is no clear evidence suggesting
clinical superiority of ARBs over ACE inhibitors [63], and
a number of drugs in both classes are labeled for children.
Food and Drug Administration (FDA) approval for chil-
dren under 6 years old is expected soon for a number of
ARBs.
Combination therapy with an ACE inhibitor and an ARB
should be considered for patients who continue to show
proteinuria while undergoing monotherapy, since it is
effective in further reducing proteinuria (and progression
of CKD) in adults [63, 64]. Experience in children is
positive but very limited [65–68], and the increased risk of
hyperkalemia and renal failure should be realized [69].
Therefore, for improved control of hypertension without
proteinuria, the combination of single RAS blockade with a
diuretic is preferable. The use of fixed-dose combinations
of RAS antagonists with a thiazide diuretic may be an
option in adolescents where compliance is an issue, but less
so in younger children where frequent dose adjustments are
required [46].
From trials in hypertensive patients without renal disease
it appears that the blood pressure lowering effect, per se, is
relevant for cardiovascular risk protection, without any
class-specific benefits. Therefore, in essential hypertension,
the choice of agents should be guided by the matching of
the side effects profile of the individual drugs to the patient-
specific risk factor profile [47]. In patients with CKD,
meta-analyses of adult trials demonstrated superior reno-
protection by ACE inhibitors, even after adjustment for
blood pressure and urine protein excretion [70]. There is no
conclusive evidence as to whether the inhibition of the
renin–angiotensin system is superior to other antihyperten-
sives in non-proteinuric CKD patients [59,71,72]. Recom-
mendations for adults prefer to err on the side of caution
and suggest a low threshold for considering CKD patients
proteinuric (200 mg protein/g creatinine in spot urine) [42].
Diuretics are less commonly used in children with CKD
than in adults with CKD, due to the preponderance of
hypodysplastic kidney disorders, which frequently present
as salt-losing nephropathies. In patients with evidence of
hypervolemia, thiazides and loop diuretics have proven
most useful for controlling volume overload, and they have
a very good side-effects profile. It should be remembered
that, while thiazides are a popular first-line therapy in mild-
to-moderate CKD, they are less effective when glomerular
filtration rate (GFR) falls below 60 ml/min per 1.73 m
2
body surface area, and they are ineffective below 30 ml/min
per 1.73 m
2. Therefore, furosemide should be preferred and
used in adequate doses for CKD stages 4 and 5. Mineral-
ocorticoid receptor antagonists (e.g. spironolactone) are
theoretically attractive in CKD, due to their synergistic
actions with RAS antagonists, and the new selective receptor
blocker eplerenone is devoid of anti-androgenic side effects.
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therapy with RAS antagonists) is limited by the potentiated
risk of hyperkalemia. During diuretic therapy, patients should
be monitored for volume depletion and electrolyte distur-
bances. Long-acting formulations help to increase patient
compliance [42].
Calciumchannelblockersareverypotentanti-hypertensive
drugs and,therefore,usefulas add-ontherapy inchildrenwith
resistant hypertension. Dihydropyridine (DHP) drugs (e.g.
nifedipine, amlodipine) act mainly as vasodilators and do not
have cardiac side effects. Amlodipine has pediatric labeling
and is available as a suspension, and doses need not to be
adjusted to renal function.
However, DHP-type calcium channel blockers (CCBs)
increase intra-glomerular pressure and proteinuria, while
non-DHP-type calcium channel blockers (e.g. verapamil
and diltiazem) have an additional anti-proteinuric effect. In
a long-term clinical trial of elderly patients with type II
diabetic nephropathy, non-DHP calcium channel blockers
showed as equally an effective slowing of CKD progres-
sion, reduction of proteinuria and antihypertensive efficacy
as did the ACE inhibitor lisinopril (while both were
superior to the beta blocker atenolol [73]). However, there
are no published safety data on any of the non-DHPs in
children with hypertension, so they should be used with
caution due to their known prolongation of the PR interval
in adults [74].
Intravenous administration of nicardipine is an option for
controlling hypertensive crises, especially when the level of
renal function is unclear or changing rapidly. It has been
used safely, even in very small children with hypertension,
despite reports of hypotension in normotensive newborns
with asphyxia [74].
Beta blockers can be used as second-line therapy for
renal hypertension in children. However, they are contra-
indicated in asthma and can cause fatigue. All beta blockers
require dose reduction with progression of CKD. They
should be used with caution in heart failure, and their
adverse metabolic effects make them less suitable for
diabetics. The largest clinical experience, especially for
infants, is available for propranolol. A sustained-release
form of this drug allows once daily administration in larger
children. However, other agents, such as atenolol, which
have the advantage of being both long acting and β1-
selective, may be preferred in clinical practice.
Other drugs are used less commonly, mainly due to their
more severe side-effects profiles. Alpha blockers (such as
prazosin) can be used in patients who also require them for
control of bladder emptying or Raynaud’s phenomenon.
Centrally acting alpha agonists (such as clonidine) act via
reduction of sympathetic nervous outflow. Rebound hyper-
tension after discontinuation is a major problem of this
drug. The vasodilators hydralazine and minoxidil are less
suitable in CKD as they are less effective and cause salt and
water retention.
The aim of antihypertensive management is the regres-
sion of end-organ damage (especially LVH) and the
lowering of blood pressure below target values while
minimizing drug side effects. The currently recommended
treatment goal in hypertensive patients with CKD is a blood
pressure of < 130/80 mmHg in adults [42, 47] and < 90th
percentile in children [46]. However, a meta-analysis of 11
randomized trials in non-diabetic adults with CKD showed
differing results for proteinuric and non-proteinuric
patients: while there was no increase in adverse renal
outcomes with higher blood pressure in non-proteinuric
patients, ideal systolic blood pressure for proteinuric
patients (> 1 g per day) was 110–129 mmHg. In proteinuric
patients, renal survival decreased, with systolic blood
pressures below 110 mmHg and above 130 mmHg. These
data are hard to interpret conclusively, as persistent
hypertension during treatment may also be a reflection of
more severe underlying disease [70]. In children, the
pending results of the ESCAPE trial may help us to
elucidate optimal blood pressure targets.
Conclusion
Adequate management of hypertension in CKD requires an
active screening approach in order to prevent the significant
renal deterioration and cardiovascular morbidity and mor-
tality associated with high blood pressure. Owing to the
plethora of different pathophysiological mechanisms in-
volved, a whole range of therapeutic options is available.
Non-pharmacological options should not be disregarded for
obese children or for children on hemodialysis. Inhibitors of
the renin–angiotensin system should be preferred for
proteinuric patients and, probably, also for non-proteinuric
patients. Multiple drug therapy is often necessary to reach
target blood pressure below the 90th percentile. For this,
diuretics and calcium channel blockers are the most suitable
options.
Questions
(Answers appear after the reference list)
Indicate the correct answer (only one).
1. Hypertension in CKD
(a) is mainly a feature of the later stages of CKD.
(b) is caused by volume overload with normal total
peripheral resistance.
(c) increases renal blood flow and, therefore, helps to
maintain residual renal function.
368 Pediatr Nephrol (2008) 23:363–371(d) can be caused by fluid overload, sympathetic
nervous system hyperactivity and/or activation of
the renin–angiotensin system.
2. In patients on hemodialysis with hypertension:
(a) serum sodium levels are not indicative of total
body sodium load.
(b) reduction of fluid overload by intensified dialysis
will swiftly lower blood pressure.
(c) low sodium dialysate causes intra-dialytic hypo-
tensive symptoms and is therefore not advisable.
3. Adequate control of blood pressure
(a) is hard to achieve with monotherapy. Therefore
fixed-dose combination therapy should be started
as first-line therapy.
(b) is possible in a large number of hemodialysis
patients on strict fluid management without anti-
hypertensive drugs.
(c) can be assumed once a patient has normal clinic
blood pressure values.
(d) makes screening for end-organ damageunnecessary.
4. Diuretics:
(a) thiazides should always be preferred to loop
diuretics due to their longer duration of action.
(b) loop diuretics should always be preferred to
thiazides due to their more potent diuretic action.
(c) diuretics can be dosed sparingly in CKD due to
greater sensitivity of the nephrons.
(d) in a patient with a GFR of less than 30 ml/min per
1.73 m
2 body surface area, thiazides should be
preferred to loop diuretics.
(e) diuretics have additional antihypertensive efficacy
if hypertension is still uncontrolled by renin–
angiotensin system blockade.
5. ACE inhibitors:
(a) retard progression of CKD only because they
lower blood pressure.
(b) retard progression of CKD only because they
reduce proteinuria.
(c) should not be used in proteinuric patients who
already receive angiotensin receptor blockers.
(d) may cause hyperkalemia, increased serum creati-
nine, hypotension and cough but are generally
well tolerated.
(e) should not be used in patients with polyuria, as
they are mild diuretics.
6. Therapeutic life-style changes:
(a) renal hypertension is usually so pronounced that
pharmacological treatment is needed, and burden-
ing patients with therapeutic life-style changes is
therefore unnecessary.
(b) low salt diet is not necessary in obese children.
(c) there are no studies to show that weight loss,
healthy diet, increased exercise or cessation of
(passive) smoking are helpful in children with
CKD.
7. Iatrogenic hypertension:
(a) erythropoietin (EPO)-induced hypertension is
mainly due to the increase in hematocrit.
(b) calcium channel blockers may be a specific
therapy for EPO-induced hypertension.
(c) beta blockers may be a specific therapy for EPO-
induced hypertension.
(d) growth hormone causes salt and water retention
with clinically relevant hypertension in children
with ESRD.
(e) cyclosporine A causes hypertension via constric-
tion of the efferent glomerular arteriole.
8. Thetargetbloodpressureinpharmacologicaltreatmentis:
(a) the 95th age- and height-dependent percentile in
all children with CKD.
(b) the 50th percentile in children with CKD stage 4
and above.
(c) independent of co-morbid diseases.
(d) still being debated but at least the 90th percentile
in children with end-organ damage or CKD.
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